Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q3 2021 · 10-Q
Revenue$349.27K$349.27K+201.3% vs Q3 2020 Net Income-$1.35M-$1.35MN/M vs Q3 2020 EPS Diluted-$0.13-$0.13N/M vs Q3 2020 Operating Income-$1,375,999N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-394.0%+8666.7 pt vs Q3 2020
Net margin-386.8%+6134.5 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 12, 2021 · 43 d after period end